MALVERN, Pa. - Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage pharmaceutical company with a market capitalization of $67 million specializing in the development of treatments for neurodegenerative ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

Researchers at the Indian Institute of Technology, Guwahati, in partnership with leading institutions around the world, have ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...